With social media fueling the huge demand for drugs like Ozempic, Rybelsus, Wegovy, and Mounjaro, which are helping people to lose more weight than any previous weight loss medications, it’s no surprise that manufacturers have had trouble keeping up. And the recent approval of Eli Lilly’s Zepbound, which is the same drug, Mounjaro, approved already for diabetes, but renamed specifically for weight management, will only add to that demand. Novo Nordisk which manufactures Ozempic Wegovy Rybelsus has held back new starter doses to Wegovy in order to make sure that those on the weight-loss drug could continue receiving their injections even though the manufacturing schedules and availability are limited.
[time-brightcove not-tgx=”true”]
But as with many situations in which supply far exceeds demand, questionable versions of these drugs are making their way into desperate patients’ hands, and doctors are concerned about what exactly these versions contain. Online sellers are taking advantage of the situation to make money, and selling Wegovy knockoffs that may or may not contain semaglutide. Novo Nordisk still holds the…
